

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on January 14, 2004.

Teresa A. Wert

Name



Signature



P&G Case 9066M2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

KENNETH DOUGLAS VINSON

Serial No.: 10/688,118

Filed: October 17, 2003

:

: Confirmation No.:

: Group Art Unit:

: Examiner:

For: Paper Softening Compositions Containing Low Levels Of High Molecular Weight Polymers And Soft Tissue Paper Products Comprising Said Compositions

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. **37 C.F.R. §1.97(b)(3)** - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. **37 C.F.R. §1.97(b)(4)** - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. **37 C.F.R. §1.97(c) with fee payment** - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case)**. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

(1) **(For use with applications filed prior to or on June 30, 2003.)** Copies of the cited documents are enclosed.

OR

(2) **(For use with applications filed after June 30, 2003.)** In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

(3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. ___, filed ___. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

(4) Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

(5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.


(6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

FOR: KENNETH DOUGLAS VINSON

By


Stephen T. Murphy
Attorney for Applicant(s)
Registration No. 42,917
(513) 634-4268

Date: 14 January 2004
Customer No. 27752
(IDS.doc) (Last Revised 10/10/03)

Please type a plus sign (+) inside this box → []
JAN 16 2004

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

Application Number	10/688,118
Confirmation Number	
Filing Date	October 17, 2003
First Named Inventor	Kenneth Douglas Vinson
Group Art Unit	
Examiner Name	
Attorney Docket Number	9066M2

SHEET 1 of 3

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	U.S. PATENT DOCUMENT Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document, MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	3,301,746		Sanford, et al.	01-31-1967	
	2	3,473,576		Amneus	10-21-1969	
	3	3,573,164		Friedberg et al.	03-30-1971	
	4	3,700,623		Kleim	10-24-1972	
	5	3,772,076		Kleim	11-13-1973	
	6	3,812,000		Salvucci, Jr. et al.	05-21-1974	
	7	3,821,068		Salvucci, Jr. et al.	05-21-1974	
	8	3,934,005		Albert	01-20-1976	
	9	3,974,025		Ayers	08-10-1976	
	10	4,011,389		Langdon et al.	03-08-1977	
	11	4,191,609		Trokhann	03-04-1980	
	12	4,208,459		Becker et al.	06-17-1980	
	13	4,239,065		Trokhann	12-16-1980	
	14	4,266,962		Kersting et al.	05-12-1981	
	15	4,300,981		Carstens	11-17-1981	
	16	4,413,087		Bernot	11-01-1983	
	17	4,447,413		Rippstein, Jr.	05-08-1984	
	18	4,510,081		Bronner et al.	04-09-1985	
	19	4,528,239		Trokhann	07-09-1985	
	20	4,637,859		Trokhann	01-20-1987	
	21	4,874,465		Cochrane et al.	10-17-1989	
	22	4,981,557		Bjorkquist	01-01-1991	
	23	5,059,282		Ampulski et al.	10-22-1991	
	24	5,215,626		Ampulski et al.	06-01-1993	
	25	5,221,435		Smith	06-22-1993	
	26	5,228,954		Vinson et al.	07-20-1993	
	27	5,246,545		Ampulski et al.	09-21-1993	
	28	5,264,082		Phan et al.	11-23-1993	
	29	5,405,499		Vinson	04-11-1995	
	30	5,415,737		Phan et al.	05-16-1995	
	31	5,487,813		Vinson et al.	01-30-1996	
	32	5,499,198		Gaidos et al.	03-12-1996	
	33	5,510,000		Phan et al.	04-23-1996	
	34	5,525,345		Warner et al.	06-11-1996	
	35	5,525,575		Chamberlain	06-11-1996	
	36	5,538,595		Trokhann et al.	07-23-1996	
	37	5,543,067		Phan et al.	08-06-1996	
	38	5,573,637		Ampulski et al.	11-12-1996	
	39	5,611,890		Vinson et al.	03-18-1997	
	40	5,637,743		Contet et al.	06-10-1997	
	41	5,656,132		Farrington et al.	08-12-1997	
	42	5,750,492		Contet et al.	05-12-1998	
	43	5,753,079		Jenny et al.	05-19-1998	
	44	5,814,188		Vinson et al.	09-29-1998	
	45	6,103,793		Osmond	08-15-2000	
	46	6,162,329		Vinson et al.	04-01-1998	
	47	6,214,771	B1	Dexter	04-10-2001	
	48	6,228,223	B1	Thebrin et al.	05-08-2001	

① 49	6,420,013	B1	Vinson et al.	07-16-2002	
50	6,547,928	B2	Barnholtz et al.	04-15-2003	

JAN 16 2004
U.S. PATENT AND TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Office ²	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	51	GB	2 107 986	A	Montedison SpA	05-11-1983		
	52	EP	0617164	A1	Kimberly-Clark	09-28-1994		
	53	EP	0677612	A2	Kimberly-Clark	10-18-1995		
	54	EP	0688901	A2	Kimberly-Clark	12-27-1995		
	55	WO	00/22231		Procter & Gamble	04-20-2000		
	56	WO	00/22233		Procter & Gamble	04-20-2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	57	TARANAKI NUCHEM LIMITED, Lo-Drift*, Spray Drift Reducer, February 19, 2003, Tapuae Partnership, New Plymouth, New Zealand.	
	58	CIBA SPECIALTY CHEMICALS, INC., Ciba® Percol® E20, September 2002, Ciba Specialty Chemicals Corporation, Suffolk, Virginia.	
	59	HEPING O. ZHU, ROBIN W. DEXTER, ROBERT D. FOX, DONALD L. REICHARD, ROSS D. BRAZEE, H. E. OZKAN, Droplet Size And Viscosity Effects In Recirculated Polymer Spray Solutions, July 25, 2003, Tektran Agricultural Research Service, Wooster, Ohio, www.nal.usda.gov/ttic/tektran/data/000007/05/0000070555.html .	
	60	TERRA INTERNATIONAL, INC., Subcide™, Nonionic Polymer Carrier & Drift Retardant, Riverside® Serves Agriculture, Sioux City, Iowa.	
	61	HELENA CHEMICAL COMPANY, Adjuvants, July 25, 2003, Helena Chemical Company Western Business Unit, www.helenachemical-west.com/products/adj_products.htm .	
	62	ERDAL OZKAN, Drift Can and Should Be Reduced to a Minimum, Do "Drift Retardant" Chemical Work?, Ag News, Volume 4-No.3 June-July 2002, The Ohio State University, The United States Department of Agriculture, Van Wert County, Ohio, www.kleinschmidt.5@osu.edu .	
	63	SCHOOL OF AGRONOMY AND HORTICULTURE, THE CENTRE FOR PESTICIDE APPLICATION AND SAFETY, The Use of Adjuvants For Reducing Spray Drift, August 14, 2002, The University of Queensland Gatton, Gatton, Queensland 4343 Australia, www.aghort.uq.edu.au-cpas/info-adjuvant-reducingdrift.html .	
	64	Hermans, et al. in U.S. Statutory Invention Registration H1672 published August 5, 1997.	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.